New combo therapy offers hope for patients with resistant stomach cancer
NCT ID NCT06208748
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This study tests a new drug combination (bezuclastinib plus sunitinib) in 40 adults with advanced gastrointestinal stromal tumors (GIST) that worsened despite sunitinib treatment. The goal is to see if the combination can delay cancer growth. Participants take both drugs by mouth, and researchers monitor tumor changes and genetic markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Sylvester Comprehensive Cancer Center, University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.